{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:23:17Z","timestamp":1788326597664,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Histochem J"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1007\/s10735-004-2186-6","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T06:23:55Z","timestamp":1103610235000},"page":"647-653","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Cornelia","family":"Hauser-kronberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Dandachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjc.6600943","volume":"88","author":"L Arnould","year":"2003","unstructured":"Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J (2003) Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 88: 1587?1591.","journal-title":"Br J Cancer"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","volume":"195","author":"JM Bartlett","year":"2001","unstructured":"Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke, TG (2001) Evaluating HER2 amplication and overexpression in breast cancer. J Pathol 195: 422?428.","journal-title":"J Pathol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/path.1354","volume":"199","author":"JM Bartlett","year":"2003","unstructured":"Bartlett JM, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199: 411?417.","journal-title":"J Pathol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","volume":"45","author":"I Bieche","year":"1999","unstructured":"Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M (1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45: 1148?1156.","journal-title":"Clin Chem"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.MP.0000052102.90815.82","volume":"16","author":"M Bilous","year":"2003","unstructured":"Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, Van De Vijver M (2003) Current Perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 16: 173?182.","journal-title":"Mod Pathol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/01.LAB.0000024360.48464.A4","volume":"82","author":"N Dandachi","year":"2002","unstructured":"Dandachi N, Dietze O, Hauser-Kronberger C (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82: 1007?1014.","journal-title":"Lab Invest"},{"issue":"Suppl.1","key":"CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000066204","volume":"63","author":"A Di Leo","year":"2002","unstructured":"Di Leo A, Dowsett M, Horten B, Penault-Llorca F (2002) Current status of HER2 testing. Oncology 63 (Suppl. 1): 25?32.","journal-title":"Oncology"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.1313","volume":"199","author":"M Dowsett","year":"2003","unstructured":"Dowsett M, Bartlett J, Ellis I, Salter J, Hills M, Mallon E, Watters A, Cooke T, Paish C, Wencyk P, Pinder S (2003) Correla-tion between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199: 418?423.","journal-title":"J Pathol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/clinchem\/47.6.990","volume":"47","author":"CA Foy","year":"2001","unstructured":"Foy CA, Parkes HC (2001) Emerging homogeneous DNA-based technologies in the clinical laboratory. Clin Chem 47: 990?1000.","journal-title":"Clin Chem"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/modpathol.3880372","volume":"14","author":"WM Hanna","year":"2001","unstructured":"Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A (2001) Defining a test for HER-2\/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 14: 677?685.","journal-title":"Mod Pathol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/07357900009012176","volume":"18","author":"RC Johnson","year":"2000","unstructured":"Johnson RC, Ricci A, Jr, Cartun RW, Ackroyd R, Tsongalis GJ (2000) p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 18: 336?342.","journal-title":"Cancer Invest"},{"key":"CR12","first-page":"923","volume":"9","author":"H Joensuu","year":"2003","unstructured":"Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J (2003) Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 9: 923?930.","journal-title":"Clin Cancer Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1373\/49.2.219","volume":"49","author":"M Konigshoff","year":"2003","unstructured":"Konigshoff M, Wilhelm J, Bohle RM, Pingoud A, Hahn M (2003) HER-2\/neu gene copy number quantified by real-time PCR: com-parison of gene amplification, heterozygosity, and immunohisto-chemical status in breast cancer tissue. Clin Chem 49: 219?229.","journal-title":"Clin Chem"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1440-1827.2001.01255.x","volume":"51","author":"H Kumamoto","year":"2001","unstructured":"Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R (2001) Chromogenic in situ hybridization analysis of HER-2\/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51: 579?584.","journal-title":"Pathol Int"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/clinchem\/47.5.844","volume":"47","author":"E Lyon","year":"2001","unstructured":"Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT (2001) Quantification of HER2\/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem 47: 844?851.","journal-title":"Clin Chem"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1525-1578(10)60471-0","volume":"5","author":"A Millson","year":"2003","unstructured":"Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MC, Hanna W, Wittwer CT, Seth A, Lyon E (2003) Comparison of two quantitative polymerase chain reaction methods for detect-ing HER2\/neu amplification. J Mol Diagn 5: 184?190.","journal-title":"J Mol Diagn"},{"key":"CR17","first-page":"63","volume":"13","author":"G Pauletti","year":"1996","unstructured":"Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridiza-tion. Oncogene 13: 63?72.","journal-title":"Oncogene"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1006111117877","volume":"52","author":"MD Pegram","year":"1998","unstructured":"Pegram MD, Pauletti G, Slamon DJ (1998) HER-2\/neu as a predic-tive marker of response to breast cancer therapy. Breast Cancer Res Treat 52: 65?77.","journal-title":"Breast Cancer Res Treat"},{"key":"CR19","first-page":"3645","volume":"9","author":"C Pellegrini","year":"2003","unstructured":"Pellegrini C, Falleni M, Marchetti A, Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G, Bosari S (2003) HER-2\/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluores-cence in situ Hybridization, and Immunohistochemistry. Clin Can-cer Res 9: 3645?3652.","journal-title":"Clin Can-cer Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"MF Press","year":"1997","unstructured":"Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ (1997) HER-2\/neu gene amplification characterized by fluorescence in situ hybridiza-tion: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894?2904.","journal-title":"J Clin Oncol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1309\/WMN8-VTR5-DUGF-X12L","volume":"116","author":"SJ Schnitt","year":"2001","unstructured":"Schnitt SJ, Jacobs TW (2001) Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 116: 806?810.","journal-title":"Am J Clin Pathol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and sur-vival with amplification of the HER-2\/neu oncogene. Science 235: 177?182.","journal-title":"Science"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian can-cer. Science 244: 707?712.","journal-title":"Science"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","volume":"157","author":"M Tanner","year":"2000","unstructured":"Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola, J (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2\/ neu oncogene amplification in archival breast cancer samples. Am J Pathol 157: 1467?1472.","journal-title":"Am J Pathol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","volume":"19","author":"RR Tubbs","year":"2001","unstructured":"Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19: 2714?2721.","journal-title":"J Clin Oncol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/00000478-200207000-00009","volume":"26","author":"RR Tubbs","year":"2002","unstructured":"Tubbs RR, Skacel M, Pettay J, Powell R, Myles J, Hicks D, Sreenan J, Roche P, Stoler MH, Hainfeld J (2002a). Interobserver interpre-tative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2\/neu amplification in invasive mammary carci-noma. Am J Surg Pathol 26: 908?913.","journal-title":"Am J Surg Pathol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0002-9440(10)61106-6","volume":"160","author":"RR Tubbs","year":"2002","unstructured":"Tubbs RR, Pettay J, Skacel M, Powell R, Stoler M, Roche P, Hainfeld J (2002b) Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybrid-ization for detection of Her-2\/neu gene amplification. Am J Pathol 160: 1589?1595.","journal-title":"Am J Pathol"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1021399923825","volume":"77","author":"AD Watters","year":"2003","unstructured":"Watters AD, Going JJ, Cooke TG, Bartlett JM (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77: 109?114.","journal-title":"Breast Cancer Res Treat"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/modpathol.3880582","volume":"15","author":"J Zhao","year":"2002","unstructured":"Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z (2002) Determina-tion of HER2 Gene Amplification by Chromogenic In Situ Hybridization (CISH) in Archival Breast Carcinoma. Mod Pathol 15: 657?665.","journal-title":"Mod Pathol"}],"container-title":["The Histochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-004-2186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10735-004-2186-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10735-004-2186-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T21:08:16Z","timestamp":1586034496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10735-004-2186-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["DO00002186"],"URL":"https:\/\/doi.org\/10.1007\/s10735-004-2186-6","relation":{},"ISSN":["1567-2379","1573-6865"],"issn-type":[{"value":"1567-2379","type":"print"},{"value":"1573-6865","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}